Şunu aradınız:: authentic product for you (Danca - Almanca)

memo/14/266 what mhealth can do for you
memo/14/266 – was mobile-health-dienste für sie tun können

clinical investigation of medicinal products for the treatment of acute ischemic stroke
c linical investigation of medicinal products for the treatment of acute is c h e m ic stroke

clinical investigation of medicinal products for prevention and the treatment of osteoporosis in men
c linical investigation of medicinal products for prevention and the treatment of osteoporosis in men

concept paper on the development of a cpmp note for guidance on the evaluation of medicinal products for treatment of migraine
concept paper on the development of a cpmp note for guidance on the evaluation of medicinal products for treatment of migraine

clinical investigation of medicinal products for the treatment of venous thrombo- embolic disease
c linical investigation of medicinal products for the treatment of venous thrombo-embolic d isease

clinical investigation of medicinal products for the treatment of cardiac failure (revision)
c linical investigation of medicinal products for the treatment of cardiac failure (revision)

guidance on pre- approval information for registration of new veterinary medicinal products for food producing animals with respect to antimicrobial resistance
guidance on pre-approval information for registration of new veterinary medicinal products for food producing animals with respect to antimicrobial resistance

et opdateret risk management plan, skal forefindes som beskrevet i chmp guideline on risk management systems for medicinal products for human use. ke r ik te dle mi ge læ
risikomanagementsysteme für humanarzneimittel vorgelegt werden. itte n eim arz

emea/ cvmp/ 344/ 99 conduct of efficacy studies for intramammary products for use in cattle
ellada/greece

i henhold til chmps ”guideline on risk management systems for medicinal products for human use”, bør den opdaterede rmp indsendes samtidig som den næste periodic safety update report (psur).
entsprechend der chmp-richtlinie für risiko-management-systeme für humanarzneimittel, sollte der überarbeitete rmp zusammen mit dem nächsten „periodic safety update report (psur)“ eingereicht werden.